Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ingenol mebutate→

Ingenol mebutate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
75567-37-2
PubChem CID
6918670
Molecular formula
C25H34O6
Molecular weight
430.5 g/mol
Drug class
Diterpene estertopical cytotoxic agent for actinic keratosis (withdrawn in EU)
Mechanism of action
Induces rapid cell death and inflammatory responses in treated epidermal cells. The precise molecular pathways are not fully defined; post-marketing evidence raised concerns about increased risk of skin malignancies.
Indications / reported uses
  • Historical topical indication: treatment of actinic keratosis in adults. The EU marketing authorisation for Picato was withdrawn in 2020 following concerns about skin malignancy risk; it should not be presented as a currently authorised EU treatment.

Sources: EMA — Picato referral and withdrawal decision · NLM MeSH — Ingenol mebutate · FDA product information

Identification source: PubChem record (CID 6918670). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ingenol mebutate Environmental Risk Assessment (ERA) (the Ingenol mebutate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.